TransCode Therapeutics Expands Oncology Pipeline with Key License Agreement

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers, has made a significant strategic move by entering into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. This agreement grants TransCode the rights to develop three promising drug candidates—UIO-524, UIO-525, and UIO-526—including all in-licensed and owned rights previously held by Unleash. In exchange, Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock, which is convertible into an equal number of common shares and represents 6.8% of TransCode's common stock on a fully diluted basis. This transaction underscores TransCode's aggressive expansion of its oncology pipeline, positioning it as a key player in the competitive biotech landscape.

The lead candidate from this deal, UIO-524, is a next-generation oncolytic adenovirus engineered to selectively replicate in malignant cells and cancer-associated stroma, delivering a multi-cytokine immune-activating payload aimed at treating solid tumors. Initially targeting muscle-invasive bladder cancer, UIO-524 represents a cutting-edge approach in cancer therapy, designed to harness the body's immune system to fight tumors more effectively. This addition complements TransCode's existing lead asset, TTX-MC138, which is advancing toward a Phase 2a clinical trial and focuses on treating metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company's portfolio, now bolstered by these new candidates, aims to mobilize the immune system to recognize and destroy cancer cells, offering hope for patients with difficult-to-treat cancers. For more details, investors and interested parties can view the full press release via the provided hyperlink, which is part of the broader coverage by BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN, ensuring widespread dissemination of this news.

This development is not just a corporate milestone but a potential game-changer in oncology research. By integrating UIO-524 into its pipeline, TransCode is leveraging innovative technologies to address unmet medical needs in cancer treatment, particularly for aggressive forms like muscle-invasive bladder cancer. The company's focus on both RNA therapeutics and immuno-oncology highlights a multifaceted strategy to combat cancer, which could lead to more effective and personalized therapies in the future. As TransCode continues to advance its clinical trials, this news reinforces its commitment to pioneering treatments that could improve patient outcomes and quality of life. For ongoing updates, stakeholders are encouraged to follow the company's newsroom, accessible through the provided links, to stay informed about progress in this critical area of medical science.